Nature Communications (Sep 2019)
A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein
- Aimin Tang,
- Zhifeng Chen,
- Kara S. Cox,
- Hua-Poo Su,
- Cheryl Callahan,
- Arthur Fridman,
- Lan Zhang,
- Sangita B. Patel,
- Pedro J. Cejas,
- Ryan Swoyer,
- Sinoeun Touch,
- Michael P. Citron,
- Dhanasekaran Govindarajan,
- Bin Luo,
- Michael Eddins,
- John C. Reid,
- Stephen M. Soisson,
- Jennifer Galli,
- Dai Wang,
- Zhiyun Wen,
- Gwendolyn J. Heidecker,
- Danilo R. Casimiro,
- Daniel J. DiStefano,
- Kalpit A. Vora
Affiliations
- Aimin Tang
- Department of Infectious Diseases and Vaccines Research, Merck & Co., Inc
- Zhifeng Chen
- Department of Infectious Diseases and Vaccines Research, Merck & Co., Inc
- Kara S. Cox
- Department of Infectious Diseases and Vaccines Research, Merck & Co., Inc
- Hua-Poo Su
- Department of Structural Chemistry and Chemical Biotechnology, Merck & Co., Inc
- Cheryl Callahan
- Department of Infectious Diseases and Vaccines Research, Merck & Co., Inc
- Arthur Fridman
- Department of Scientific Informatics, Merck & Co., Inc.
- Lan Zhang
- Department of Infectious Diseases and Vaccines Research, Merck & Co., Inc
- Sangita B. Patel
- Department of Structural Chemistry and Chemical Biotechnology, Merck & Co., Inc
- Pedro J. Cejas
- Department of Infectious Diseases and Vaccines Research, Merck & Co., Inc
- Ryan Swoyer
- Department of Infectious Diseases and Vaccines Research, Merck & Co., Inc
- Sinoeun Touch
- Department of Infectious Diseases and Vaccines Research, Merck & Co., Inc
- Michael P. Citron
- Department of Infectious Diseases and Vaccines Research, Merck & Co., Inc
- Dhanasekaran Govindarajan
- Department of Infectious Diseases and Vaccines Research, Merck & Co., Inc
- Bin Luo
- Department of Pharmacology, Merck & Co., Inc.
- Michael Eddins
- Department of Structural Chemistry and Chemical Biotechnology, Merck & Co., Inc
- John C. Reid
- Department of Structural Chemistry and Chemical Biotechnology, Merck & Co., Inc
- Stephen M. Soisson
- Department of Structural Chemistry and Chemical Biotechnology, Merck & Co., Inc
- Jennifer Galli
- Department of Infectious Diseases and Vaccines Research, Merck & Co., Inc
- Dai Wang
- Department of Infectious Diseases and Vaccines Research, Merck & Co., Inc
- Zhiyun Wen
- Department of Infectious Diseases and Vaccines Research, Merck & Co., Inc
- Gwendolyn J. Heidecker
- Department of Infectious Diseases and Vaccines Research, Merck & Co., Inc
- Danilo R. Casimiro
- Department of Infectious Diseases and Vaccines Research, Merck & Co., Inc
- Daniel J. DiStefano
- Department of Infectious Diseases and Vaccines Research, Merck & Co., Inc
- Kalpit A. Vora
- Department of Infectious Diseases and Vaccines Research, Merck & Co., Inc
- DOI
- https://doi.org/10.1038/s41467-019-12137-1
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 13
Abstract
Respiratory syncytial virus (RSV) is a leading cause of infant hospitalization. Here, the authors isolate a human monoclonal antibody that binds to a highly conserved epitope on the RSV fusion protein, neutralizes RSV A and B subtypes equipotently and is protective in the cotton rat model.
